Glenmark Pharmaceuticals' Q4 FY 2025-26 Quarterly Results

Result Summary

• Glenmark Pharmaceuticals Ltd reported a 0.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 21.2%.
• Its expenses for the quarter were down by 0.9% QoQ and up 10.8% YoY.
• The net profit decreased 25.3% QoQ and increased 6779.2% YoY.
• The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd stood at 10.68 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glenmark Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for manufacturing and marketing of branded and generic formulations. The company operates globally, providing a wide range of products across various therapeutic areas, including dermatology, respiratory, and oncology. Glenmark has a significant presence in both emerging and developed markets. As of the latest available data, the company has been actively involved in research and development to innovate within the pharmaceutical sector. However, specific recent major developments are not available in the provided data.

Revenue

In the fourth quarter of FY26, Glenmark Pharmaceuticals Ltd reported a total income of ₹3959.67 crores, reflecting a modest quarter-over-quarter (QoQ) increase of 0.4% from ₹3945.08 crores in Q3FY26. There was a significant year-over-year (YoY) increase of 21.2% compared to ₹3267.89 crores in Q4FY25. This upward trend in revenue can be attributed to the company's strategic focus on expanding its product portfolio and market reach. The consistent growth in total income highlights the company's ability to enhance its revenue streams over the past year.

Profitability

The company experienced a decline in profitability on a QoQ basis, with profit before tax (PBT) decreasing by 27.4% to ₹387.77 crores in Q4FY26 from ₹534.00 crores in Q3FY26. However, on a YoY basis, there was an extraordinary increase of 4765.4% from ₹7.97 crores in Q4FY25. The tax expense for Q4FY26 was ₹86.45 crores, down 33.9% QoQ, but up substantially by 2308.1% YoY. Profit after tax (PAT) for Q4FY26 stood at ₹301.31 crores, showing a 25.3% decrease QoQ, but an exceptional rise of 6779.2% YoY from ₹4.38 crores in Q4FY25. These figures indicate a substantial improvement in profitability compared to the previous year.

Operating Metrics

The total expenses for Q4FY26 were reported at ₹3198.50 crores, which is a slight decrease of 0.9% from ₹3226.75 crores in Q3FY26. Compared to Q4FY25, expenses increased by 10.8% from ₹2887.09 crores. This indicates that the company has managed to control its expenses quarter-over-quarter while incurring higher expenses year-over-year, potentially due to increased operational activities. The earnings per share (EPS) for Q4FY26 were ₹10.68, down 25.2% QoQ from ₹14.28 in Q3FY26. However, YoY, EPS saw a dramatic rise of 6575.0% from ₹0.16 in Q4FY25, reflecting the company's significant earnings growth over the past year.